Division of Gastroenterology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
Department of Pathology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
Gastrointest Endosc. 2019 Apr;89(4):759-768. doi: 10.1016/j.gie.2018.10.048. Epub 2018 Nov 14.
There is controversy about finding intestinal metaplasia (IM) of the gastric cardia on biopsy. The most recent American College of Gastroenterology guideline comments that IM cardia is not more common in patients with Barrett's esophagus (BE). It provides limited guidance on whether the cardia should be treated when patients with BE undergo endoscopic eradication therapy (EET) and whether the cardia should undergo biopsy after ablation. The aims of our study were to determine the frequency in the proximal stomach of (1) histologic gastric cardia mucosa and (2) IM cardia. A third aim was to explore the frequency of advanced pathology (dysplasia and adenocarcinoma) in the cardia after patients with BE have undergone EET.
Consecutive patients undergoing esophagogastroduodenoscopy between January 2008 and December 2014 who had proximal stomach biopsies were included. Patients who had histologically confirmed BE were compared with those without BE.
Four hundred sixty-two patients, 289 with BE and 173 without BE, were included. Histologically confirmed cardiac mucosa was found in 81.6% of all patients. This was more frequent in those with versus without BE (86% vs 75%; odds ratio [OR], 2.06; 95% confidence interval [CI], 1.28-3.32; P = .003). IM cardia was more common in the BE group (17% vs 7%; OR, 2.67; 95% CI, 1.38-5.19; P = .004). Advanced pathology was more likely in the patients with BE who had undergone EET.
Cardiac mucosa is present in most patients who undergo endoscopy for upper GI symptoms. IM cardia is more common in patients with BE than those without. Advanced histologic changes in the cardia were seen only in the subgroup of patients with BE who had undergone EET.
关于胃贲门活检时发现肠上皮化生(IM)存在争议。最近的美国胃肠病学院指南评论称,巴雷特食管(BE)患者的贲门 IM 并不更常见。该指南仅就 BE 患者行内镜下消除治疗(EET)时是否应治疗贲门以及消融后是否应行贲门活检提供了有限的指导。本研究旨在确定(1)近端胃组织学贲门黏膜和(2)贲门 IM 的发生频率。第三个目的是探讨 BE 患者行 EET 后贲门高级别病变(异型增生和腺癌)的发生率。
纳入 2008 年 1 月至 2014 年 12 月期间行食管胃十二指肠镜检查且行近端胃活检的连续患者。比较有组织学证实的 BE 患者与无 BE 患者。
共纳入 462 例患者,其中 289 例有 BE,173 例无 BE。所有患者中均发现组织学证实的贲门黏膜,有 BE 者更常见(86% vs 75%;优势比 [OR],2.06;95%置信区间 [CI],1.28-3.32;P =.003)。BE 组贲门 IM 更常见(17% vs 7%;OR,2.67;95% CI,1.38-5.19;P =.004)。EET 后 BE 患者更可能出现高级别病理改变。
大多数因上消化道症状而行内镜检查的患者均存在贲门黏膜。BE 患者的贲门 IM 比无 BE 者更常见。仅在 EET 后的 BE 患者亚组中观察到贲门的高级别组织学改变。